Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

By K. Burris, T. Molski, Cen Xu, Elaine Ryan, K. Tottori, T. Kikuchi, F. Yocca, P. Molinoff. Journal of Pharmacology and Experimental Therapeutics, 2002

947 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a3853a9208741e3df5ee2d1760f14b0d431d6ff8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Bryan L. Roth
2. Brian K. Kobilka
3. David E. Nichols
4. Arthur Christopoulos
5. M. von Zastrow

In Molecular Biology

1. Bryan L. Roth
2. Brian K. Kobilka
3. David R. Sibley
4. Arthur Christopoulos
5. M. von Zastrow

Citations in the corpus

• Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007, background): “This partial D2 agonism (Burris et al., 2002; Cosi et al., 2006) is postulated to lead to “dopamine system stabilization”, i.”
• Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology (2003, methodology): “Prior studies have supported the notion that the unique clinical actions of aripiprazole are the result of its partial agonist properties at the D2L receptor (Burris et al, 2002; Inoue et al, 1996; Tamminga, 2002).”
• Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. (2003, neutral): “Completed study 52 (50) 61 (60) 67 (66) 62 (63) 242 (60) Discontinued 51 (50) 40 (40) 34 (34) 37 (37) 162 (40) Reasons for discontinuation Adverse event 17 (17) 11 (11) 8 (8) 8 (8) 44 (11) Noncompliance 0 (0) 1 (1) 2 (2) 1 (1) 4 (1) Insufficient clinical response 17 (17) 9 (9) 8 (8) 8 (8) 42 (10) Ot”